Almac Discovery Limited

10 patents currently held · Updated Nov 15, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

Ending by 2030

Mar 2032

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Apr 13, 2027
The maintenance fee for AKT inhibitor compounds for treatment of cancer (US 9,156,853) comes due Apr 13, 2027. Unpaid by Oct 13, 2027, it lapses early.
1 fee due May 7, 2027
The maintenance fee for 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) (US 11,807,646) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
1 fee due Jun 29, 2027
The maintenance fee for Inhibitors of AKT activity (US 9,221,838) comes due Jun 29, 2027. Unpaid by Dec 29, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 10 of 10

Patent	Title	Status	Expires	Confidence
US 9,221,838	Inhibitors of AKT activity In force Term ends Mar 5, 2032 · From the USPTO record	In force	Term ends Mar 5, 2032	From the USPTO record
US 9,156,853	AKT inhibitor compounds for treatment of cancer In force Term ends Mar 25, 2033 · From the USPTO record	In force	Term ends Mar 25, 2033	From the USPTO record
US 9,714,244	Substituted pyrido[4,3-d]pyrimidines as Wee-1 inhibitors In force Term ends Apr 11, 2034 · From the USPTO record	In force	Term ends Apr 11, 2034	From the USPTO record
US 9,850,247	Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors In force Term ends Dec 19, 2034 · From the USPTO record	In force	Term ends Dec 19, 2034	From the USPTO record
US 11,053,213	Pharmaceutical compounds In force Term ends Jul 26, 2037 · From the USPTO record	In force	Term ends Jul 26, 2037	From the USPTO record
US 11,208,413	Pyrimidopyrimidinones Useful as WEE-1 Kinase Inhibitors In force Term ends Mar 12, 2038 · High confidence	In force	Term ends Mar 12, 2038	High confidence
US 12,679,841	Pyrimidopyrimidinones Useful as WEE-1 Kinase Inhibitors In force Term ends Mar 12, 2038 · High confidence	In force	Term ends Mar 12, 2038	High confidence
US 11,807,646	4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) In force Term ends Mar 19, 2039 · From the USPTO record	In force	Term ends Mar 19, 2039	From the USPTO record
US 12,466,805	Pharmaceutical compounds In force Term ends Oct 1, 2040 · From the USPTO record	In force	Term ends Oct 1, 2040	From the USPTO record
US 12,324,837	ROR1-specific antigen binding molecules In force Term ends Apr 29, 2041 · From the USPTO record	In force	Term ends Apr 29, 2041	From the USPTO record

Also on record, not counted in the 10: 5 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 9 no status recorded

List them